Cipla Ltd.
Snapshot View

View in App

Prices View details >>

900.65 +12.80 ▲1.4%

31 March 2023, 04:01:00 PM
Volume: 76,126

Overview View Details >>

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.cipla.com
Market Cap 72,696.02 Cr.
Enterprise Value(EV) 71,714.15 Cr. 2022-09
Financial Indicators
Earnings per share (EPS) 32.69 Trailing Twelve Months Ending 2022-12
Price-Earning Ratio (PE) 27.55 Trailing Twelve Months Ending 2022-12
Industry PE 32.41 Trailing Twelve Months Ending 2022-12
Book Value / Share 286.32 Trailing Twelve Months Ending 2022-12
Price to Book Value 3.15 Calculated using Price: 900.65
Dividend Yield 0.56 Period Ending 2022-03
No. of Shares Subscribed 80.72 Cr. 807,150,593 Shares
FaceValue 2
Company Profile
The company is in the business of manufacturing, developing, and marketing wide range of branded and generic formulations and Active Pharmaceutical Ingredients (APIs). The company has its wide network of manufacturing, trading and other incidental operations in India and International markets.

Delivery View Details >>

Delivered Qty
Traded Qty

Performance View Details >>

1 Day
+1.44%
1 Week
+2.70%
1 Month
-0.60%
3 Month
-16.22%
6 Month
-19.24%
1 Year
-11.57%
2 Year
+10.48%
5 Year
+65.79%
10 Year
+137.17%

Ratios View Details >>

9 years 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03 2021-03 2022-03
Return on Equity (%) 14.89 12.10 12.61 8.72 10.65 10.37 10.09 14.13 13.10
Return on Capital Employed (%) 19.05 15.33 13.24 8.28 10.20 11.94 12.53 17.85 17.24
Return on Assets (%) 10.49 7.85 7.28 4.97 6.52 6.50 6.56 9.95 9.94

Balance Sheet View Details >>

Particulars 10 years 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2022-09* Rs. Cr.
Shh. Funds 10,050 10,801 11,516 12,544 14,229 15,012 15,763 18,327 20,842 21,884
Non Curr. Liab. 2,028 2,418 1,407 4,513 4,259 4,646 2,972 1,660 622 117
Curr. Liab. 2,564 3,881 7,776 3,374 3,832 3,772 4,393 4,591 4,913 5,309
Minority Int. 50 180 350 438 352 332 294 259 276 285
Equity & Liab. 14,692 17,281 21,049 20,869 22,673 23,762 23,423 24,837 26,652 27,596
Non Curr. Assets 9,040 9,689 12,208 12,064 11,859 11,335 11,717 11,628 11,925 11,690
Curr. Assets 5,652 7,591 8,841 8,736 10,814 12,425 11,704 13,181 14,711 15,906
Misc. Exp. not W/O
Total Assets 14,692 17,281 21,049 20,869 22,673 23,762 23,423 24,837 26,652 27,596

Profit Loss View Details >>

Particulars 10 years 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2022-12 Rs. Cr. TTM
Net Sales 10,173 11,345 13,595 14,394 15,156 16,362 17,132 19,160 21,763 22,274
Other Income 265 166 208 229 358 477 369 270 322 405
Total Income 10,439 11,511 13,803 14,623 15,513 16,839 17,501 19,429 22,085 22,679
Total Expenditure -8,040 -9,184 -11,115 -11,919 -12,329 -13,265 -13,951 -14,911 -17,251 -17,671
PBIDT 2,398 2,327 2,688 2,704 3,184 3,574 3,550 4,518 4,834 5,008
Interest -146 -168 -207 -159 -114 -168 -197 -161 -106 -93
Depreciation -373 -505 -754 -1,323 -1,323 -1,326 -1,175 -1,068 -1,052 -1,116
Taxation -463 -400 -332 -180 -250 -570 -631 -889 -934 -1,052
Exceptional Items -78 -182 -58
PAT 1,417 1,254 1,395 1,042 1,419 1,510 1,547 2,401 2,559 2,689
Minority Interest -16 -48 -23 -29 -6 35 47 16 -30 -44
Share Associate -12 -25 -12 -7 -3 -17 -47 -13 -13 -7
Other Related Items
Consolidated Net Profit 1,388 1,181 1,360 1,006 1,411 1,528 1,547 2,405 2,517 2,638
Adjusted EPS 17 15 17 13 18 19 19 30 31 33

Cash Flow View Details >>

Particulars 10 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr.
Cash Fr. Operatn. 1,398 1,563 1,173 1,741 2,382 1,463 1,691 3,068 3,755 3,326
Cash Fr. Inv. -2,063 -1,250 -941 -4,523 -1,310 -854 -1,669 104 -2,387 -1,872
Cash Fr. Finan. 718 -266 165 3,104 -1,326 -385 -349 -2,949 -1,240 -1,600
Net Change 53 48 397 322 -254 223 -326 224 129 -146
Cash & Cash Eqvt 143 176 564 858 610 853 508 742 790 658

Shareholding Pattern View Details >>

9 Qtrs 2020-12 (%) 2021-03 (%) 2021-06 (%) 2021-09 (%) 2021-12 (%) 2022-03 (%) 2022-06 (%) 2022-09 (%) 2022-12 (%)
Promoter 36.70 36.73 36.72 36.12 36.11 33.63 33.61 33.61 33.61
Public 63.30 63.27 63.28 63.88 63.89 66.37 66.39 66.39 66.39
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details >>

Wed, 29 Mar 2023
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 (Listing Regulations) we herein mention the schedule of Analyst / Institutional Investor Meetings with the Company.
Fri, 17 Mar 2023
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
In compliance with the provisions of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we hereby notify that the Operations and Administrative Committee of the Company on 17th March 2023 has allotted 6 663 fully paid-up equity shares of INR 2 each pursuant to exercise of employee stock options under the Employee Stock Option Scheme 2013-A of the Company.Consequently the issued subscribed and paid-up share capital of the Company stands increased to INR 1 61 43 01 186 comprising of 80 71 50 593 equity shares of face value INR 2 each.
Tue, 14 Mar 2023
Announcement under Regulation 30 (LODR)-Diversification / Disinvestment
In compliance with the provisions of Regulation 30 of the SEBI Listing Regulations we hereby notify that the Company and its wholly owned subsidiaries Cipla (EU) Limited UK and Meditab Holdings Limited Mauritius have entered into a Share Purchase Agreement with Africa Capitalworks SSA 3 on 14th March 2023 for sale of 51.18% stake held in Cipla Quality Chemical Industries Limited (CQCIL) Uganda. Subsequent to the sale CQCIL will cease to be a subsidiary of the Company. Details required to be disclosed under the SEBI Listing Regulations 2015 read with Circular No. CIR/CFD/CMD/4/2015 dated 9th September 2015 have been provided in Annexure - I to this letter.

Technical Scans View Details >>

Fri, 31 Mar 2023
Opening at Low Opening at Low
Closing Above Previous High Closing Above Previous High
Making Higher Highs for 3 days Making Higher Highs for 3 days
Close Within 52 Week Low Zone Close Within 52 Week Low Zone
Close Above Last Week High Close Above Last Week High

Related Stocks View Details >>

  • SALES
Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 235,878.62 983.10 -0.8%
Dr. Reddy's Laboratories Ltd. 76,960.86 4,624.15 +1.3%
Divi's Laboratories Ltd. 75,014.78 2,826.00 +0.3%
Apollo Hospitals Enterprise Ltd. 61,962.56 4,309.40 -1.3%
Torrent Pharmaceuticals Ltd. 52,030.91 1,543.40 +0.2%
Zydus Lifesciences Ltd. 49,749.83 491.00 +0.1%
Abbott India Ltd. 46,932.38 22,086.55 +1.6%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-12 56.00 983.10 -0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-12 21.13 4,624.15 +1.3%
Divi's Laboratories Ltd. Consolidated 2022-12 31.30 2,826.00 +0.3%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-12 81.03 4,309.40 -1.3%
Torrent Pharmaceuticals Ltd. Consolidated 2022-12 62.86 1,543.40 +0.2%
Zydus Lifesciences Ltd. Consolidated 2022-12 24.11 491.00 +0.1%
Abbott India Ltd. Standalone 2022-12 50.50 22,086.55 +1.6%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-12 4.26 983.10 -0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-12 3.50 4,624.15 +1.3%
Divi's Laboratories Ltd. Consolidated 2022-12 6.03 2,826.00 +0.3%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-12 10.04 4,309.40 -1.3%
Torrent Pharmaceuticals Ltd. Consolidated 2022-12 8.19 1,543.40 +0.2%
Zydus Lifesciences Ltd. Consolidated 2022-12 2.88 491.00 +0.1%
Abbott India Ltd. Standalone 2022-12 15.85 22,086.55 +1.6%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 0.03 983.10 -0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 0.18 4,624.15 +1.3%
Divi's Laboratories Ltd. Consolidated 2022-03 0.00 2,826.00 +0.3%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 0.47 4,309.40 -1.3%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 0.68 1,543.40 +0.2%
Zydus Lifesciences Ltd. Consolidated 2022-03 0.25 491.00 +0.1%
Abbott India Ltd. Standalone 2022-03 0.00 22,086.55 +1.6%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 7.21 983.10 -0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 11.93 4,624.15 +1.3%
Divi's Laboratories Ltd. Consolidated 2022-03 28.16 2,826.00 +0.3%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 21.60 4,309.40 -1.3%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 13.18 1,543.40 +0.2%
Zydus Lifesciences Ltd. Consolidated 2022-03 15.51 491.00 +0.1%
Abbott India Ltd. Standalone 2022-03 29.95 22,086.55 +1.6%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 7.21 983.10 -0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 11.93 4,624.15 +1.3%
Divi's Laboratories Ltd. Consolidated 2022-03 28.16 2,826.00 +0.3%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 21.60 4,309.40 -1.3%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 13.18 1,543.40 +0.2%
Zydus Lifesciences Ltd. Consolidated 2022-03 15.51 491.00 +0.1%
Abbott India Ltd. Standalone 2022-03 29.95 22,086.55 +1.6%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 38,654.49 983.10 -0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 21,545.20 4,624.15 +1.3%
Divi's Laboratories Ltd. Consolidated 2022-03 8,959.83 2,826.00 +0.3%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 14,662.60 4,309.40 -1.3%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 8,508.04 1,543.40 +0.2%
Zydus Lifesciences Ltd. Consolidated 2022-03 15,265.20 491.00 +0.1%
Abbott India Ltd. Standalone 2022-03 4,919.27 22,086.55 +1.6%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 3,405.82 983.10 -0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 2,182.50 4,624.15 +1.3%
Divi's Laboratories Ltd. Consolidated 2022-03 2,960.45 2,826.00 +0.3%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 1,101.10 4,309.40 -1.3%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 777.18 1,543.40 +0.2%
Zydus Lifesciences Ltd. Consolidated 2022-03 2,326.40 491.00 +0.1%
Abbott India Ltd. Standalone 2022-03 798.70 22,086.55 +1.6%

FAQ's On Cipla Ltd.

What is Cipla share price?
Can I buy Cipla shares now?
What is the Dividend Yield of Cipla?
What is the Market Cap of Cipla?
What are the key metrics to analyse Cipla?
What is the 52 Week High and Low of Cipla?
What is the trend of Cipla share price?